SCHEMBL13229591

SCHEMBL13229591

O=C(NC1=CC=CC1)c1c[nH]c2ccsc2c1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.49
HTR3A P46098 1/20 0.49
CFTR P13569 15/20 0.37
ADORA3 P0DMS8 1/20 0.34
ADRB3 P13945 1/20 0.34
TBXA2R P21731 1/20 0.34
SLC6A2 P23975 1/20 0.34
AGTR1 P30556 1/20 0.34
MC4R P32245 1/20 0.34
PTGS2 P35354 1/20 0.34
SLC6A3 Q01959 1/20 0.34
ALDH1A1 P00352 2/20 0.33
TP53 P04637 1/20 0.33
RAB9A P51151 1/20 0.33
LMNA P02545 1/20 0.33
MAPK1 P28482 1/20 0.33
GABRA1 P14867 1/20 0.33
GABRB1 P18505 1/20 0.33
GABRA5 P31644 1/20 0.33
GABRA3 P34903 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13229590 0.81 CFTR (0.37) CFTRADORA3ADRB3TBXA2RSLC6A2
SCHEMBL13229581 0.78 CYP3A4 (0.55) CYP3A4HTR3ACFTRALDH1A1TP53
SCHEMBL13229587 0.76 CFTR (0.63) CYP3A4HTR3ACFTRALDH1A1TP53
SCHEMBL13229620 0.75 CYP3A4 (0.47) CYP3A4HTR3ACFTRADORA3ADRB3
SCHEMBL13229624 0.75 CFTR (0.48) CYP3A4HTR3ACFTRADORA3ADRB3
SCHEMBL13229697 0.73 CYP3A4 (0.49) CYP3A4HTR3ACFTRALDH1A1TP53
SCHEMBL14780622 0.72 CFTR (0.65) CYP3A4HTR3ACFTRRAB9AGABRA1
SCHEMBL2793777 0.72 CYP3A4 (0.50) CYP3A4HTR3AALDH1A1
SCHEMBL14780628 0.70 CFTR (0.69) CYP3A4HTR3ACFTRADORA3ADRB3
SCHEMBL6708336 0.70 CYP3A4 (0.49) CYP3A4HTR3AALDH1A1RAB9AMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140235668-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VPI VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-08-21 US disclosed
US-20130231364-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-09-05 US disclosed
US-8399479-B2 Modulators of cystic fibrosis transmembrane conductance regulator VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-03-19 US disclosed
US-20100168158-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140235668-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VPI CFTR, ABCB1, ABCC1 CYP3A4 3757/4885HTR3A 4289/4885CFTR 1/4885
US-20100168158-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, ABCB1, ABCC1 CYP3A4 3621/4885HTR3A 3751/4885CFTR 1/4885
US-20130231364-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, ABCB1, ABCC1 CYP3A4 3621/4885HTR3A 3751/4885CFTR 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.